Loading clinical trials...
Loading clinical trials...
An Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With Sarcoidosis
Conditions
Interventions
all subjects will receive maraviroc 300mg orally twice a day for 6 weeks
Bronchoscopy with bronchoalveolar lavage
+2 more
Locations
1
United States
Dorothy P. and Richard P. Simmons center for Interstitial lung Disease at the University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Start Date
January 1, 2014
Primary Completion Date
May 1, 2015
Completion Date
May 1, 2015
Last Updated
December 3, 2025
NCT07073963
NCT05746039
NCT04402086
NCT07359690
NCT06573723
NCT06510894
Lead Sponsor
Kevin F. Gibson
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions